Drug Profile


Alternative Names: TP-434

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Acetamides; Antibacterials; Pyrrolidines; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Intra-abdominal infections; Urinary tract infections
  • Phase I Respiratory tract infections

Most Recent Events

  • 02 Aug 2017 Tetraphase Pharmaceuticals announces intention to submit MAA to the EMA for Intra-abdominal infections at the end of this quarter
  • 25 Jul 2017 Tetraphase Pharmaceuticals announces intention to submit NDA to the US FDA for Intra-abdominal infections in the first quarter of 2018
  • 25 Jul 2017 Efficacy and adverse event data from the phase III IGNITE4 trial in Intra-abdominal infections, which met its primary endpoints, released by Tetraphase Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top